DRUG-INDUCED ORTHOSTATIC HYPOTENSION

被引:34
作者
SCHOENBERGER, JA
机构
[1] Department of Preventive Medicine, Rush-Presbyterian-St Luke’S Medical Center, Chicago, Illinois, 60612
关键词
D O I
10.2165/00002018-199106060-00002
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Drug-induced orthostatic hypotension is an important clinical problem. When symptomatic, it is poorly tolerated by the patient, and can be a cause for discontinuing treatment. It may have more serious consequences if it leads to syncope, falls and injury, or to sustained loss of perfusion of vital organs resulting in heart attack or stroke. Orthostatic hypotension is easily detected by procedures available to all physicians, who should maintain a high index of suspicion when prescribing drugs commonly known to cause this condition, especially in the elderly. Since the medical conditions calling for the use of these drugs are extremely prevalent, the screening and monitoring of orthostatic hypotension should be instituted as a routine precaution in appropriate patients. Hypertension affects two-thirds of elderly patients. Orthostatic hypotension is an infrequent adverse effect of most of the drugs in current use in the treatment of hypertension; it is, however, more common with alpha-1-blockers (first dose), adrenergic blockers and centrally acting drugs. Sudden loss of blood volume, or excess diuresis, may precipitate orthostatic hypotension in any hypertensive patient. Drugs used for the treatment of psychiatric illnesses are all associated with a significant incidence of orthostatic hypotension: phenothiazines, tricyclic antidepressants and monoamine oxidase inhibitors. Cardiovascular drugs associated with hypotension include dopamine agonists, antianginals and antiarrhythmics.
引用
收藏
页码:402 / 407
页数:6
相关论文
共 17 条
[1]  
Baldessarine R.J., Drugs and the treatment of psychiatric disorders, The pharmacologic basis of therapeutics, (1985)
[2]  
Brunner H.R., Waeber B., Nussberger J., Principles and practice of angiotensin-converting enzyme inhibitors, Cardiovascular drug therapy, pp. 732-760, (1990)
[3]  
Campbell A.J., Drug treatment as a cause of falls in old age. A review of the offending agents, Drugs & Aging, 1, pp. 289-302, (1991)
[4]  
Preliminary report: effect of encainide and flecainide on mortality in a randomised trial of arrhythmia suppression after myocardial infarction, New England Medical Journal, 312, pp. 406-412, (1989)
[5]  
Cornoni-Huntley J., LaCroix A.Z., Havlik R.J., Race and sex differentials in the impact of hypertension in the United States: the National Health and Nutrition Examination Survey I, Epidemiologic Follow-up Study (1982–1984), Archives of Internal Medicine, 149, pp. 780-788, (1989)
[6]  
Report of the Joint National Committee on the Detection, Evaluation and Treatment of High Blood Pressure, Archives of Internal Medicine, 148, pp. 1023-1038, (1988)
[7]  
Frishman W.H., Beta-adrenergic blockers, Medical Clinics of North America, 72, pp. 37-54, (1988)
[8]  
Mader S.L., Aging and postural hypotension, Journal of the American Geriatric Society, 37, pp. 129-137, (1989)
[9]  
Mader S.L., Orthostatic hypotension, Medical Clinics of North America, 73, pp. 1337-1349, (1989)
[10]  
McMahon G.F., Alpha<sub>1</sub>blocking agents, In Management of essential hypertension,chapter IX, pp. 501-531, (1990)